Standout Papers
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (2017)
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials (2018)
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events (2017)
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus (2018)
Immediate Impact
2 from Science/Nature 106 standout
Citing Papers
Understanding mechanisms of antioxidant action in health and disease
2023 Standout
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
2023 Standout
Works of Greg Fulcher being referenced
A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations
2019
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Greg Fulcher | 7548 | 3312 | 2847 | 62 | 9.2k | |
| Mehul Desai | 7621 | 3333 | 3202 | 49 | 9.2k | |
| Avivit Cahn | 7371 | 2872 | 3007 | 111 | 8.8k | |
| Thomas A. Zelniker | 6545 | 2725 | 2744 | 67 | 8.4k | |
| Wayne Shaw | 6814 | 2919 | 2670 | 36 | 8.1k | |
| Eri Kato | 5783 | 2396 | 2397 | 45 | 7.2k | |
| Maximilian von Eynatten | 7968 | 3409 | 3119 | 114 | 10.7k | |
| Ingrid Gause‐Nilsson | 5914 | 2401 | 2606 | 68 | 7.3k | |
| Hans J. Woerle | 11126 | 5444 | 5008 | 88 | 12.9k | |
| Julia Kuder | 4736 | 3409 | 1865 | 59 | 8.4k | |
| Steven P. Marso | 8596 | 3068 | 3303 | 72 | 10.7k |
All Works
Loading papers...